Verrica Pharmaceuticals (VRCA) Total Non-Current Liabilities (2020 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Total Non-Current Liabilities of $16.9 million for Q1 2026, down 71.01% year-over-year from $58.4 million in Q1 2025, and down 2.34% quarter-over-quarter from $17.3 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $16.9 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 71.01% year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $16.9 million (down 71.01% YoY), while the FY2025 annual figure was $17.3 million, down 72.93% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $16.9 million, down from $17.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $65.3 million in Q2 2024, with the low at $6.8 million in Q2 2023.
- The 4-year median for Total Non-Current Liabilities is $54.8 million (2023), against an average of $47.1 million.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities jumped 861.71% in 2024, then sank 72.93% in 2025.
- Verrica Pharmaceuticals' Total Non-Current Liabilities stood at $61.8 million in 2023, then gained by 3.49% to $64.0 million in 2024, then tumbled by 72.93% to $17.3 million in 2025, then dropped by 2.34% to $16.9 million in 2026.
- Business Quant data shows VRCA's Total Non-Current Liabilities at $16.9 million in Q1 2026, $17.3 million in Q4 2025, and $53.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.87 Bn | 78.87 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.40 Bn | 60.22 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.36 Bn | 54.22 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.91 Bn | 28.60 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.17 Bn | 9.78 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.32 Bn |
| 10 | Verrica Pharmaceuticals | 101.84 Mn | 90.64 Mn | - | 23.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.30 Mn |
| Mar 31, 2026 | 16.92 Mn |
| Dec 31, 2025 | 17.32 Mn |
| Sep 30, 2025 | 53.25 Mn |
| Jun 30, 2025 | 54.80 Mn |
| Mar 31, 2025 | 58.36 Mn |
| Dec 31, 2024 | 63.99 Mn |
| Jun 30, 2024 | 65.31 Mn |
| Mar 31, 2024 | 64.80 Mn |
| Dec 31, 2023 | 61.83 Mn |
| Sep 30, 2023 | 54.84 Mn |
| Jun 30, 2023 | 6.79 Mn |
| Jun 30, 2020 | 38.70 Mn |
| Mar 31, 2020 | 37.76 Mn |